Related Experiment Video
Updated: Apr 12, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Secondary hyperparathyroidism disease stabilization following calcimimetic therapy
João Frazão1, Mariano Rodriguez2
1Nephrology Research and Development Unit and School of Medicine , University of Porto , Porto , Portugal.
Calcimimetics, like cinacalcet, effectively stabilize secondary hyperparathyroidism (SHPT) by improving treatment goal achievement. These drugs enhance calcium-sensing receptor sensitivity, offering a valuable option for managing moderate to advanced SHPT.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Secondary hyperparathyroidism (SHPT) management often fails to meet therapeutic targets with standard treatments.
- Standard SHPT therapies include calcium, vitamin D, and phosphate binders, which are frequently insufficient.
- Alterations in calcium-sensing receptor (CaR) and vitamin D receptor expression, alongside parathyroid cell proliferation, characterize SHPT.
Purpose of the Study:
- To evaluate the efficacy of calcimimetics in stabilizing secondary hyperparathyroidism (SHPT).
- To assess the role of type II calcimimetics in reversing SHPT-associated molecular and cellular changes.
- To determine if calcimimetic treatment can improve patient achievement of serum parathyroid hormone (PTH), calcium, and calcium-x-phosphorus product (Ca x P) targets.
Main Methods:
- Review of preclinical studies on type II calcimimetics' effects on CaR and vitamin D receptor expression and parathyroid cell proliferation.
- Analysis of clinical trial data from SHPT patients treated with the calcimimetic cinacalcet.
- Assessment of changes in serum PTH, calcium, phosphorus, and Ca x P levels in response to cinacalcet therapy.
Main Results:
- Calcimimetics demonstrated the ability to reverse key molecular and cellular alterations associated with SHPT in preclinical models.
- Cinacalcet treatment significantly reduced serum PTH, calcium, phosphorus, and Ca x P levels in SHPT patients.
- Improvements were observed across varying disease severities and were sustained during long-term therapy (up to 4 years).
Conclusions:
- Preclinical and clinical data support the use of calcimimetics for stabilizing moderate and advanced SHPT.
- Calcimimetic therapy, exemplified by cinacalcet, offers a promising approach to achieve and maintain therapeutic goals in SHPT.
- Calcimimetics provide both theoretical and empirical evidence for effective disease stabilization in SHPT management.
More Related Videos
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
07:12Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
Published on: August 17, 2022
Related Concept Videos
Skeleton and Calcium Homeostasis
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Urinary Tract Calculi III: Medical Management
Bone Remodeling